Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis - Wikidata - thesis-toulmin - TriplyDB

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q24630353

about

Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice IGF-1 restores visual cortex plasticity in adult life by reducing local GABA levels Neuromuscular effects of G93A-SOD1 expression in zebrafish.The association between cancer and amyotrophic lateral sclerosis.αCAR IGF-1 vector targeting of motor neurons ameliorates disease progression in ALS mice.Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise.New therapeutic targets for amyotrophic lateral sclerosis.Stem cell technology for the study and treatment of motor neuron diseases.Intercellular (mis)communication in neurodegenerative disease.Understanding ALS: new therapeutic approaches.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Altered astrocytic response to activation in SOD1(G93A) mice and its implications on amyotrophic lateral sclerosis pathogenesis.Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy.Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis.Current and emerging treatments for amyotrophic lateral sclerosis.Computational methods for identifying a layered allosteric regulatory mechanism for ALS-causing mutations of Cu-Zn superoxide dismutase 1 Could IGF-I levels play a neuroprotective role in patients with large vestibular schwannomas?Neural stem/progenitor cells differentiate into oligodendrocytes, reduce inflammation, and ameliorate learning deficits after transplantation in a mouse model of traumatic brain injury.Autocrine production of IGF-I increases stem cell-mediated neuroprotection.Role of IGF-1R in ameliorating apoptosis of GNE deficient cells.

P2860

Q33894621-2B70586E-9F77-490F-B354-63E55671BA69 Q34276055-244EC8F3-FCB2-45FB-B15C-F6FCC21FF667 Q35618849-17CF0FEE-085D-4D16-AA3C-841E689117D6 Q36031801-CF54FF6E-4DA9-4FFA-973C-9070C5041925 Q36423696-310B94DA-00B0-4FBE-8194-5C4A5294B0FE Q36487523-4AE7F5AD-3FFB-4E8E-8C40-2D78A9BAE1A1 Q37307491-554BC3BD-13AA-4D6E-A09C-3F5F19E74FD6 Q37311897-C1A0217A-81EA-48AC-95BB-47C6FF971A2E Q37816447-0C431320-359B-44D1-8F9B-5AF4EE5DE447 Q37851503-BABDC167-2ED6-4EF1-9B52-659BB3AE9818 Q37992251-789CCC22-307C-491B-8440-D493241E1EBB Q38065343-7C44DC58-DB49-4CED-87EC-76A1A16809E2 Q38573829-03CB6F8D-57CC-4B91-AA43-FBDEBE8823D2 Q38881707-C967BD68-3A74-4BCD-8276-497CBFE36ED0 Q39217922-481DC455-FAC9-4FFF-A99A-2759D5EA5E3D Q39664862-CECF28D4-4DAA-4843-A882-830EA4742237 Q42285046-25CE5AB7-10B2-47BE-89BB-6AC0A70E40FD Q42685032-3AD5D61C-325F-4560-A123-692C9041A5BE Q42694170-AE4D85CF-4DC2-4825-AC40-753E3B79DA0F Q47705965-11442B1E-019D-4C42-91AB-6DE6C3EBF6B6 Q49087870-855421C4-987B-4703-88F0-51C25DA52879 Q53655642-F51AC23C-D620-4D0F-A2FF-EAB12BFF8C2D Q54979444-020956E6-3E38-44F5-AC08-EA60EDAE034A

P2860

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q24630353

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@ast

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@en

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@nl

type

label

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@ast

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@en

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@nl

prefLabel

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@ast

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@en

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@nl

P1433

Q24630353-118990DA-D9C6-4AF1-AD2C-EF745EADE0C3

P1476

Q24630353-6278C16A-418B-4FA5-B1B7-CB6289BCD064

P2093

Q24630353-6EF41EBE-AF4F-4AE2-9B91-24DAF55F9E3E

P2860

Q24630353-00C8F7C9-EFD9-4088-BC63-B6C6FB9E0497

Q24630353-01F79741-E82A-49F8-A370-D6DF6B5F385B

Q24630353-02B80D0D-2AE2-4402-99B9-023BC2446979

Q24630353-05156EC1-362B-4CE6-98F6-49EF2F1B5CBB

Q24630353-070CF54D-526E-4873-B761-68482FAA2830

Q24630353-0E34BD89-2534-42A3-9D39-18A5FA6862BF

Q24630353-13AD79CF-265D-454B-94E9-FA296746F862

Q24630353-13C1E297-EF61-454C-A33C-DDE35BF3E092

Q24630353-193EC2C3-172E-4180-87E0-B76A294F9130

Q24630353-1B061C78-1EAC-40F9-A751-8FC74F0686F5

P304

Q24630353-239EAFCB-4E21-4A1A-92CE-FA602F92F865

P31

Q24630353-FA164791-6B34-4580-A9CF-E8D43A59BDE2

P3181

Q24630353-0115543D-EA09-403C-859D-15432A5C55EA

P356

Q24630353-B421DF4B-E1CD-4100-95FB-CBFBFC74ED39

P407

Q24630353-EAB76505-61B1-4DF0-AE75-7877BA3F24B5

P433

Q24630353-F49750B7-892A-44B2-BE45-D4E4EB0718B1

P478

Q24630353-602E7897-E129-4234-9D19-6B4A57B1215E

P50

Q24630353-2243D25B-02F3-4242-9D3F-80CE602EC31F

Q24630353-64A0BDDA-0118-4937-B45A-330F0CAF09F9

P577

Q24630353-DEF3D74B-44A3-49DB-BC87-9EF7E841666A

P5875

Q24630353-0A0727FA-EED3-41F2-85D7-879B74EAFE14

P698

Q24630353-A4D69523-7DE0-491F-B922-D9A65BCB2E51

P921

Q24630353-5736AE94-0764-4738-B298-3433D6E74A06

Q24630353-A0BDD29E-6544-4A2E-B798-C38C16BFEFDA

P932

Q24630353-86E13F92-6E30-40AC-9E7A-0B5CCF603CD1

P3181

P356

17482960802160370

P1433

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

P1476

Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis

@en

P2093

Stacey A Sakowski

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2

A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.

The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle

JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain

The insulin-like growth factor-I-mTOR signaling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth

Whole-genome analysis of sporadic amyotrophic lateral sclerosis

DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)

Misfolded CuZnSOD and amyotrophic lateral sclerosis

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis

P304

63-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3628670

http://www.w3.org/2001/XMLSchema#string

P356

10.1080/17482960802160370

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Adam D Schuyler

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5245056

http://www.w3.org/2001/XMLSchema#string

P698

18608100

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

3211070

http://www.w3.org/2001/XMLSchema#string